ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atara Biotherapeutics Inc (ATRA) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is experiencing significant negative sentiment due to legal issues, poor financial performance, and bearish technical indicators. Additionally, there are no positive trading signals or catalysts to suggest a reversal in the near term.
The technical indicators are bearish. The MACD is negatively expanding, RSI is neutral but leaning towards oversold, and moving averages indicate a downtrend (SMA_200 > SMA_20 > SMA_5). Key support levels are being tested, with S1 at 4.759 and S2 at 4.216. The stock has a 60% chance of further declines in the short term, with a potential -9.8% drop in the next week and -24.26% in the next month.
NULL identified.
Multiple class action lawsuits have been filed against Atara Biotherapeutics, citing manufacturing compliance issues and alleged false statements. These legal challenges have significantly eroded investor confidence. Additionally, hedge funds are selling the stock, with a 192.53% increase in selling activity over the last quarter.
The company's financial performance in Q4 2025 was poor. Revenue dropped by -95.13% YoY to $1,595,000, net income fell by -73.17% YoY to -$3,406,000, and EPS decreased by -78.99% YoY to -$0.25. Although gross margin improved to 93.48% (up 17.96% YoY), this is insufficient to offset the significant declines in other financial metrics.
No recent analyst rating or price target changes were provided. However, the overall sentiment is negative due to the company's financial and legal challenges.
